In partnership with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the IAC is proud to announce an upcoming accreditation program for Radiopharmaceutical Therapy.
The new program offers facilities a mechanism for demonstrating their commitment to quality and patient safety in radiopharmaceutical therapy and will join the existing IAC accreditation areas: Nuclear Cardiology; General Nuclear Medicine and Positron Emission Tomography (PET).
Proposed Standards Open for 60-Day Public Comment
IAC announces the opportunity to comment on the proposed IAC Standards and Guidelines for Radiopharmaceutical Therapy Accreditation, prior to final publication in concert with the launch of the new accreditation program.
In addition, proposed revisions to the IAC Standards and Guidelines for Nuclear/PET Accreditation are also available for public comment. All therapy Standards will be removed from the Nuclear/PET Standards and added to the Radiopharmaceutical Therapy Standards. The changes proposed for Nuclear/PET will be applied to those Standards only.
Beginning February 15, 2023, the public may visit the IAC website to comment on any of the proposed Standards until April 15, 2023.
Submit a Comment (Radiopharmaceutical Therapy)
Submit a Comment (Nuclear/PET)
Submit a Comment on Proposed Standards:
- Visit the IAC comment period website by clicking a button above;
- Select the proposed Standard you wish to comment on;
- A window will expand with the description of the existing Standard and the proposed change on the left;
- On the right, fill in your name and comment in the boxes provided;
- Hit Submit.
At the close of the comment period, the IAC Board of Directors will review all submitted comments, consider modifications as needed and vote for final approval of the Standards.
The new Standards will be posted to the website and available for download at intersocietal.org/programs/nuclear-pet/standards.